{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T05:40:58Z","timestamp":1776490858393,"version":"3.51.2"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The endocannabinoid system affects several physiological functions. A family of endocannabinoid receptors is susceptible to cannabis constituents. Cannabis is widely used in our society and following its recent legalization in Canada, we focus on how exposure to cannabis and pharmacologic cannabinoid receptor type 1 (CB1) inhibition affect lipoprotein levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Several groups have reported that exposure to cannabis does not increase weight despite the marked increase in caloric intake. In observational studies, the effect of smoked cannabis exposure on plasma lipids is variable. Some studies in specific patient populations with longer exposure to cannabis seemed to identify slightly more favorable lipoprotein profiles in the exposed group. Several larger controlled clinical trials using orally administered rimonabant, a CB1 receptor antagonist, have consistently shown relative improvements in weight and plasma levels of triglyceride and high-density lipoprotein cholesterol among patients receiving the treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The widely variable findings on the relationship of cannabis in various forms with plasma lipids preclude any definitive conclusions. Cannabis has complex effects on the cardiovascular system and its effects on lipid profile must be considered in this overall context. Further properly controlled research is required to better understand this topic.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000575","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T04:11:14Z","timestamp":1547611874000},"page":"140-146","source":"Crossref","is-referenced-by-count":18,"title":["Cannabis effects on lipoproteins"],"prefix":"10.1097","volume":"30","author":[{"given":"Julieta","family":"Lazarte","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University"},{"name":"Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University"},{"name":"Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University"},{"name":"Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University"},{"name":"Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","first-page":"10","article-title":"Analysis of trends in the prevalence of cannabis use in Canada, 1985 to 2015","volume":"29","author":"Rotermann","year":"2018","journal-title":"Health Rep"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.beem.2008.10.013","article-title":"An introduction to the endocannabinoid system: from the early to the latest concepts","volume":"23","author":"De Petrocellis","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R4-20230917","first-page":"605","article-title":"Determination and characterization of a cannabinoid receptor in rat brain","volume":"34","author":"Devane","year":"1988","journal-title":"Mol Pharmacol"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/mol.63.4.908","article-title":"The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa\/fa rats and in cultured adipocyte cells","volume":"63","author":"Bensaid","year":"2003","journal-title":"Mol Pharmacol"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00005344-200304000-00020","article-title":"Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle","volume":"41","author":"Bonz","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1111\/j.1476-5381.1996.tb15639.x","article-title":"Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves","volume":"118","author":"Ishac","year":"1996","journal-title":"Br J Pharmacol"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/jnc.12137","article-title":"Neuron-type specific cannabinoid-mediated G protein signalling in mouse hippocampus","volume":"124","author":"Steindel","year":"2013","journal-title":"J Neurochem"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrn3876","article-title":"Endocannabinoid signalling and the deteriorating brain","volume":"16","author":"Di Marzo","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol Rev"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/bbrc.1995.2437","article-title":"2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain","volume":"215","author":"Sugiura","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1021\/jm00038a020","article-title":"(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability","volume":"37","author":"Abadji","year":"1994","journal-title":"J Med Chem"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0166-2236(98)01283-1","article-title":"Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action","volume":"21","author":"Di Marzo","year":"1998","journal-title":"Trends Neurosci"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/MIB.0000000000001004","article-title":"Manipulation of the endocannabinoid system in colitis: a comprehensive review","volume":"23","author":"Leinwand","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5152\/eurjrheum.2017.17025","article-title":"The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease","volume":"4","author":"Barrie","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tips.2012.03.002","article-title":"At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction","volume":"33","author":"Montecucco","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1189\/jlb.3RU0115-021R","article-title":"Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites","volume":"97","author":"Turcotte","year":"2015","journal-title":"J Leukocyte Biol"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"R191","DOI":"10.1530\/REP-16-0167","article-title":"Endocannabinoid system and pregnancy","volume":"152","author":"Correa","year":"2016","journal-title":"Reproduction"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/er.2005-0009","article-title":"The emerging role of the endocannabinoid system in endocrine regulation and energy balance","volume":"27","author":"Pagotto","year":"2006","journal-title":"Endocr Rev"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/0091270007299358","article-title":"The role of endocannabinoid system blockade in the treatment of the metabolic syndrome","volume":"47","author":"Kakafika","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrcardio.2017.130","article-title":"Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly","volume":"15","author":"Pacher","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":"Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity","volume":"115","author":"Osei-Hyiaman","year":"2005","journal-title":"J Clin Invest"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s00125-008-1048-2","article-title":"The endocannabinoid system in obesity and type 2 diabetes","volume":"51","author":"Di Marzo","year":"2008","journal-title":"Diabetologia"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.2337\/diabetes.54.10.2838","article-title":"Activation of the peripheral endocannabinoid system in human obesity","volume":"54","author":"Engeli","year":"2005","journal-title":"Diabetes"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.2337\/db06-0812","article-title":"Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity","volume":"55","author":"Bluher","year":"2006","journal-title":"Diabetes"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2826.2008.01690.x","article-title":"Endocannabinoids, adipose tissue and lipid metabolism","volume":"20","author":"Pagano","year":"2008","journal-title":"J Neuroendocrinol"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"pii: e009099","DOI":"10.1161\/JAHA.118.009099","article-title":"Cannabinoids, the heart of the matter","volume":"7","author":"Alfulaij","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/ATVBAHA.108.168757","article-title":"Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice","volume":"29","author":"Dol-Gleizes","year":"2009","journal-title":"Arterioscl Throm Vas"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, structure, and partial synthesis of an active constituent of hashish","volume":"86","author":"Gaoni","year":"1964","journal-title":"J Am Chem Soc"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta (9)-tetrahydrocannabinol, cannabidiol and delta (9)-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Brit J Pharmacol"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cnr.2005.08.015","article-title":"Cannabis and endocannabinoid modulators: therapeutic promises and challenges","volume":"5","author":"Grant","year":"2005","journal-title":"Clin Neurosci Res"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"New Engl J Med"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","article-title":"The structure of cannabidiol","volume":"19","author":"Mechoulam","year":"1963","journal-title":"Tetrahedron"},{"key":"R36-20230917","first-page":"605","article-title":"Determination and characterization of a cannabinoid receptor in rat-brain","volume":"34","author":"Devane","year":"1988","journal-title":"Mol Pharmacol"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jcph.778","article-title":"Edible cannabis products: it is time for FDA oversight","volume":"56","author":"Benjamin","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jat\/16.5.276","article-title":"Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana","volume":"16","author":"Huestis","year":"1992","journal-title":"J Anal Toxicol"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.amjcard.2006.03.024","article-title":"Marijuana use, diet, body mass index, and cardiovascular risk factors (from the CARDIA Study)","volume":"98","author":"Rodondi","year":"2006","journal-title":"Am J Cardiol"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0195-6663(88)80017-5","article-title":"Effects of smoked marijuana on food-intake and body-weight of humans living in a residential laboratory","volume":"11","author":"Foltin","year":"1988","journal-title":"Appetite"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/aje\/kwr200","article-title":"Obesity and cannabis use: results from 2 representative national surveys","volume":"174","author":"Le Strat","year":"2011","journal-title":"Am J Epidemiol"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.2337\/dc12-2303","article-title":"Metabolic effects of chronic cannabis smoking","volume":"36","author":"Muniyappa","year":"2013","journal-title":"Diabetes Care"},{"key":"R43-20230917","first-page":"E239","article-title":"Marijuana use over 15 years, diet, body mass index and cardiovascular risk factors: the CARDIA study","volume":"111","author":"Rodondi","year":"2005","journal-title":"Circulation"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1079\/PHN2000114","article-title":"Dietary intake and nutritional status of US adult marijuana users: results from the Third National Health and Nutrition Examination Survey","volume":"4","author":"Smit","year":"2001","journal-title":"Public Health Nutr"},{"key":"R45-20230917","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.amjmed.2013.03.002","article-title":"The impact of marijuana use on glucose, insulin, and insulin resistance among US adults","volume":"126","author":"Penner","year":"2013","journal-title":"Am J Med"},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0091-3057(85)90402-2","article-title":"Changes of HDL-lipid composition as related to delta-9-THC action","volume":"22","author":"Kalofoutis","year":"1985","journal-title":"Pharmacol Biochem Be"},{"key":"R47-20230917","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/mp.2008.50","article-title":"Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses","volume":"15","author":"Jayanthi","year":"2010","journal-title":"Mol Psychiatr"},{"key":"R48-20230917","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"New Engl J Med"},{"key":"R49-20230917","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1210\/jc.2003-032056","article-title":"Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity","volume":"89","author":"Cohn","year":"2004","journal-title":"J Clin Endocr Metab"},{"key":"R50-20230917","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MOL.0b013e328352dc70","article-title":"Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production","volume":"23","author":"Yao","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"R51-20230917","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1017\/S0033291715002883","article-title":"Metabolic syndrome in people with a psychotic illness: is cannabis protective?","volume":"46","author":"Waterreus","year":"2016","journal-title":"Psychol Med"},{"key":"R52-20230917","doi-asserted-by":"crossref","first-page":"S364","DOI":"10.1093\/schbul\/sby018.887","article-title":"Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders","volume":"44","author":"Scheffler","year":"2018","journal-title":"Schizophrenia Bull"},{"key":"R53-20230917","first-page":"R345","article-title":"Antiobesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice","volume":"284","author":"Trillou","year":"2003","journal-title":"Am J Physiol-Reg I"},{"key":"R54-20230917","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2004.00374.x","article-title":"The antiobesity effect of rimonabant is associated with an improved serum lipid profile","volume":"7","author":"Poirier","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"R55-20230917","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"R56-20230917","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients \u2013 RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"key":"R57-20230917","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"New Engl J Med"},{"key":"R58-20230917","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/dc08-0386","article-title":"SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes","volume":"31","author":"Rosenstock","year":"2008","journal-title":"Diabetes Care"},{"key":"R59-20230917","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/01.CIR.82.2.495","article-title":"Atherogenic lipoprotein phenotype: a proposed genetic-marker for coronary heart-disease risk","volume":"82","author":"Austin","year":"1990","journal-title":"Circulation"},{"key":"R60-20230917","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2710.2010.01164.x","article-title":"An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity","volume":"36","author":"Christopoulou","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"R61-20230917","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"R62-20230917","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(10)60935-X","article-title":"Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial","volume":"376","author":"Topol","year":"2010","journal-title":"Lancet"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201904000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:13:29Z","timestamp":1694938409000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201904000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000575","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}